Mylan Comments on UBS ReportPITTSBURGH--(BUSINESS WIRE)--Nov. 11, 2003--In response to a report issued today by UBS analyst Steven Valiquette concerning Mylan Laboratories Inc.'s (NYSE:MYL) patent litigation with Johnson & Johnson ("J&J") about Mylan's fentanyl transdermal system, Vice Chairman and CEO Robert J. Coury said, "In view of the uncertainty of litigation, we believe it is irresponsible to publicly predict the outcome of lawsuits. Mylan cannot predict the outcome of this litigation, or any litigation, but Mylan has great respect for the courts and the legal process. This is precisely why, when asked about any litigation, it is Mylan's policy not to comment about the details of pending cases."

Mr. Coury continued, "While Mylan is not interested in trying lawsuits in the press, and we respectfully look to the courts to decide the cases in which we are involved, we must nevertheless comment upon this report that heavily impacted trading in Mylan stock today. UBS's analysts did not attend the trial and their report is based on reading initial post-trial briefs filed by the parties. Post-trial briefing is not yet closed in the case with additional briefs due to be filed, so UBS's analysis was incomplete. UBS reported that Mylan has 'essentially abandoned its noninfringement argument' and, as a result, Mr. Valiquette commented that Mylan is not likely to prevail in this litigation. Mylan has not abandoned its non-infringement argument. Mylan's position is, and has always been, that its product does not infringe any valid and enforceable claim of J&J's patent. J&J started this case asserting infringement of more than fifty claims of its patent; yet, immediately before trial, J&J withdrew its infringement argument as to all claims but four. Mylan also does not agree with UBS's characterization of the legal question presented in the case."

Mr. Coury concluded his remarks by stating, "Even if Mylan were to lose this case, Mylan would not change its previously announced earnings guidance of $1.11 to $1.18 per diluted share for fiscal year 2004."

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc. that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the final resolution of the fentanyl litigation, the impact of a decision in that litigation on future earnings, and Mylan's projected fiscal 2004 earnings. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties regarding the unresolved patent infringement allegations against the Company, including the Company's ability to successfully develop, license or otherwise acquire and introduce new products on a timely basis in relation to competing product introductions; the Company's ability to obtain required FDA approvals for new products on a timely basis; uncertainties regarding continued market acceptance of and demand for the Company's products; the Company's periodic dependence on a relatively small group of products as a significant source of its net revenue or net income; the effects of vigorous competition on commercial acceptance of the Company's products and their pricing; the high cost and uncertainty associated with compliance with extensive regulation of the pharmaceutical industry; the significant research and development expenditures the Company makes to develop products, the commercial success of which is uncertain; the possible loss of business from, or the effects of any consolidation of, the Company's concentrated customer base; the potential costs and product introduction delays that may result from the use of legal, regulatory and legislative strategies by the Company's competitors; the Company's dependence on third-party suppliers and distributors for raw materials; uncertainties regarding patent, intellectual and other proprietary property protections; the expending of substantial resources associated with litigation involving patent or other intellectual property protection of competing products; possible reductions in reimbursement rates for pharmaceutical products; possible negative effects on product pricing of current or future legislative or regulatory programs; the Company's exposure to lawsuits and contingencies associated with its business; uncertainties regarding the Company's performance under indemnification clauses in certain material agreements; the Company's exposure to risks inherent in acquisitions or joint ventures; uncertainties and matters beyond the control of management, which could affect the Company's earnings guidance, as well as the subjectivity inherent in any probability weighted analysis underlying the Company's assumptions and estimates with respect to the future; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release. In addition, the Company undertakes no duty to review or correct analysts reports except as required by law, nor should any absence of commenting in the past or future be construed as an endorsement or acceptance of any information in such reports.

    CONTACT: Mylan Laboratories Inc.
             Kris King, 724-514-1800

    SOURCE: Mylan Laboratories Inc.